Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity

Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells

(2015) Eun-Ju Ko et al.   Nanomedicine-Nanotechnology Biology and Medicine

Immune responses to vaccines involving a combined antigen–nanoparticle mixture and nanoparticle-encapsulated antigen formulation

(2014) Weifeng Zhang et al.   BIOMATERIALS

Resistance to human epidermal growth factor receptor type 2-targeted therapies

(2014) Jean-Christophe Thery et al.   EUROPEAN JOURNAL OF CANCER

CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful

(2014) H.-J. Kim et al.   Cancer Immunology Research

Bioengineering virus-like particles as vaccines

(2013) Linda H.L. Lua et al.   BIOTECHNOLOGY AND BIOENGINEERING

Allogeneic tumor cell vaccines

(2013) Sanjay Srivatsan et al.   Human Vaccines & Immunotherapeutics

Chimeric Trop2 Virus-like Particles

(2011) Rafael Cubas et al.   JOURNAL OF IMMUNOTHERAPY

Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development

(2011) Rangaiah Shashidharamurthy et al.   MEDICINAL RESEARCH REVIEWS

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles

(2010) Jae-Min Song et al.   VIROLOGY

A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

(2009) P. P. Peethambaram et al.   CLINICAL CANCER RESEARCH

Virus-like Particle (VLP) Lymphatic Trafficking and Immune Response Generation After Immunization by Different Routes

(2009) Rafael Cubas et al.   JOURNAL OF IMMUNOTHERAPY

Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells

(2009) Sheng Zhang et al.   MOLECULAR IMMUNOLOGY

Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles

(2009) Sang-Moo Kang et al.   PLoS One

The coming of age of virus-like particle vaccines

(2008) Gary T. Jennings et al.   BIOLOGICAL CHEMISTRY

The E75 HER2/neu peptide vaccine

(2008) Elizabeth A. Mittendorf et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Nanoparticles target distinct dendritic cell populations according to their size

(2008) Vania Manolova et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs

(2008) Peter S. Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine

(2008) Jarrod P. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY